Posted on 2021-05-24 in Press Release

Crohn’s Disease (CD) – Press Release

Press Release on Crohn’s Disease (CD)

According to Thelansis, the global Crohn’s disease (CD) market was estimated at ~$6,425 MN in 2020 and expected to reach ~$ 12,346 MN by the end of 2030 (10 years of markets forecasting). They attribute the high growth to the launches of biologics and biosimilars of Humira, Cimzia, and Tysabri and increased uptake of Remicade and Entocort.

Market Forecast Model-

Crohn Disease (CD) forecast

Epidemiology and patient segmentation:
According to Thelansis, globally, ~ 2.4 MN patients are being diagnosed with Crohn’s disease (CD) in 2020, among which 8MM countries comprise ~75% of the total yearly reported cases. Considering the country-level perspective, the USA and EU5 contribute around ~73% of the total diagnosed patient pool; however, in terms of market, the USA is leading considering the current disease burden and treatment cost. Diagnosed incidence trends are relatively high in the USA, EU5, and Japan, attributed to the early screening programs and the diagnosis of the patients in the early stages of the disease.


Crohn’s disease – biomarker level patient segmentation:
Molecular epidemiology study of specific biomarker mutations across country level has been given a clear understanding on patient pool across different biomarker targets (TNF-alpha, CARD15, IBD5, ATG16L1, IRGM, interleukins, and another inflammatory cytokine)

Competitive Landscape:

Current therapy: One goal of medical treatment is to suppress the inflammatory response, thereby allowing the intestinal tissue to heal and also relieve symptoms of fever, diarrhea, and abdominal pain. Medications are also used to reduce the frequency of disease flares.

There are five categories of drugs used to treat Crohn’s disease:
• Aminosalicylates (5-ASA), • Corticosteroids, • Antibiotics, • Immune modifiers, • Biologic therapies (Infliximab, Adalimumab, Natalizumab, Certolizumab pegol, etc.), • Others

Emerging therapies: As per Thelansis, based on tumor mutation evidence, some key players are into developing therapies for the treatment of Crohn’s disease, such as Celgene, Gilead Sciences, Otsuka, Galapagos, J&J, AbbVie, Boehringer Ingelheim, Allergan, UCB, Elan Pharmaceuticals, Biogen, Shire, Mitsubishi, Fast Forward, Roche, Amgen, Qu Biologics, AstraZeneca, Theravance Biopharma, GSK, Valeant Pharmaceuticals, Novartis, Landos Biopharma, Eli Lilly, Redstone Biopharma, Provention Bio, Pfizer, BMS

The annual cost of therapy:

According to the published literature review, for patients with CD, the yearly cost burden ranges from $2,952 to $20,928, including all hospitalization and non-hospitalization costs. v Pharmaceutical therapy claims accounted for the most significant proportion of direct costs (41.3%). TNF alpha was the most costly medication; approximately 10% of patients with CD had at least two claims for infliximab infusions. Hospitalization and outpatient services accounted for around 32.5% and 34.1%, respectively.

PMR Insights: KOL’s Insights / Perspective            Payer’s perspective

Clinical Trial Assessment- 

Detailed clinical trial data analysis and key product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps in determining the potential of the key assets as well as their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other important unmet needs identified through our research include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

About Thelansis:

Thelansis specializes in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area, including rare / ultra-rare and mainstream indication. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

SYNDICATED REPORTS

Contact Us:

> Delivery Office:

Bengaluru– Embassy TechVillage, Kadabeesanahalli, Bengaluru-560013 India 

Gurugram– One work Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

clientsupport@thelansis.com

> Sales office:

183 Asylum Street Hartford,
CT-06103, USA
Contact no. +1 (267) 244-6955
m.berg@thelansis.com